Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.62 |
| ▸ | APAF1 | O14727 | 1/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | GLA | P06280 | 1/20 | 0.55 |
| ▸ | GLS | O94925 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24884396 | 0.83 | LMNA (0.64) | LMNAAPAF1POLBKDM4EALDH1A1 | |
| SCHEMBL13633143 | 0.83 | LMNA (0.59) | LMNAAPAF1POLBKDM4EALDH1A1 | |
| SCHEMBL14578729 | 0.83 | LMNA (0.64) | LMNAAPAF1POLBKDM4EALDH1A1 | |
| SCHEMBL4318762 | 0.83 | LMNA (0.59) | LMNAAPAF1POLBKDM4EALDH1A1 | |
| SCHEMBL25000882 | 0.82 | LMNA (0.57) | LMNAAPAF1POLBKDM4EALDH1A1 | |
| SCHEMBL3762594 | 0.81 | KMT2A (0.64) | LMNAAPAF1POLBKDM4EALDH1A1 | |
| SCHEMBL20320332 | 0.81 | LMNA (0.56) | LMNAAPAF1POLBKDM4EALDH1A1 | |
| SCHEMBL18712864 | 0.80 | LMNA (0.60) | LMNAAPAF1POLBKDM4EALDH1A1 | |
| SCHEMBL23616393 | 0.80 | LMNA (0.60) | LMNAAPAF1POLBKDM4EALDH1A1 | |
| SCHEMBL17853363 | 0.80 | LMNA (0.56) | LMNAAPAF1POLBKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024059665-A1 | DIMERIC COMPOUNDS AS INHIBITORS OF GLYCOGEN SYNTHASE 1 (GYS1) AND METHODS OF USE THEREOF | MAZE THERAPEUTICS, INC. (US) | 2024-03-21 | — | — | WO | disclosed |
| US-20230157290-A1 | ALKENE-CONTAINING CARBOXYLATE COMPOUND AND USE THEREOF | JIANGSU YANGNONG CHEMICAL CO., LTD (CN) | 2023-05-25 | — | — | US | disclosed |
| US-20230157290-A1 | ALKENE-CONTAINING CARBOXYLATE COMPOUND AND USE THEREOF | JIANGSU YANGNONG CHEMICAL CO., LTD (CN) | 2023-05-25 | — | — | US | disclosed |
| US-20230037883-A1 | ALKENE-CONTAINING AMIDE COMPOUND AND APPLICATION THEREOF | JIANGSU YANGNONG CHEMICAL CO., LTD (CN) | 2023-02-09 | — | — | US | disclosed |
| US-20230009626-A1 | INDOLINONE COMPOUNDS FOR USE AS MAP4K1 INHIBITORS | ICHNOS SCIENCES S.A. (CH) | 2023-01-12 | — | — | US | disclosed |
| WO-2022198196-A1 | INHIBITORS OF GLYCOGEN SYNTHASE 1 (GYS1) AND METHODS OF USE THEREOF | MAZE THERAPEUTICS, INC. (US) | 2022-09-22 | — | — | WO | disclosed |
| US-11236082-B2 | EZH2 inhibitors and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-02-01 | — | — | US | disclosed |
| WO-2021068816-A1 | ALKENE-CONTAINING AMIDE COMPOUND AND USE THEREOF | 沈阳中化农药化工研发有限公司 | 2021-04-15 | — | — | WO | disclosed |
| WO-2021068820-A1 | ALKENE-CONTAINING CARBOXYLATE COMPOUND AND USE THEREOF | 沈阳中化农药化工研发有限公司 | 2021-04-15 | — | — | WO | disclosed |
| WO-2021068815-A1 | CARBOXYLIC ACID ESTER COMPOUND AND APPLICATION THEREOF | 沈阳中化农药化工研发有限公司 | 2021-04-15 | — | — | WO | disclosed |
| US-20120101091-A1 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-04-26 | — | — | US | disclosed |
| WO-2011123937-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | UNIVERSITY HEALTH NETWORK (CA) | 2011-10-13 | — | — | WO | disclosed |
| US-7897622-B2 | 2-amido-5-oxo/thio-benzoic acid derivatives; hepatitis C virus infection; synergistic with another inhibitor of HCV polymerase or immunomodulatory agent such as interferons | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-03-01 | — | — | US | disclosed |
| US-7897622-B2 | 2-amido-5-oxo/thio-benzoic acid derivatives; hepatitis C virus infection; synergistic with another inhibitor of HCV polymerase or immunomodulatory agent such as interferons | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-03-01 | — | — | US | disclosed |
| US-20100286131-A1 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-11-11 | — | — | US | disclosed |
| US-20100286131-A1 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-11-11 | — | — | US | disclosed |
| US-20100190779-A1 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-07-29 | — | — | US | disclosed |
| US-20100190779-A1 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-07-29 | — | — | US | disclosed |
| US-20080045516-A1 | Viral Polymerase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-02-21 | — | — | US | disclosed |
| US-20080045516-A1 | Viral Polymerase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286131-A1 | VIRAL POLYMERASE INHIBITORS | POLR2A, POLR2H, POLR2B | LMNA 4099/4885APAF1 1544/4885POLB 15/4885 |
| US-20230009626-A1 | INDOLINONE COMPOUNDS FOR USE AS MAP4K1 INHIBITORS | MAP4K1, MAP4K2, MAP4K4 | LMNA 1226/4885APAF1 3328/4885POLB 3665/4885 |
| US-20230157290-A1 | ALKENE-CONTAINING CARBOXYLATE COMPOUND AND USE THEREOF | DDT, ALK, ACMSD | LMNA 4522/4885APAF1 2949/4885POLB 4253/4885 |
| US-20080045516-A1 | Viral Polymerase Inhibitors | POLR2A, POLR2H, POLR2E | LMNA 3643/4885APAF1 1250/4885POLB 11/4885 |
| US-20120101091-A1 | VIRAL POLYMERASE INHIBITORS | POLR2A, POLR2H, POLR2E | LMNA 1290/4885APAF1 1456/4885POLB 10/4885 |
| US-11236082-B2 | EZH2 inhibitors and uses thereof | EZH2, EZH1, BMI1 | LMNA 2203/4885APAF1 2157/4885POLB 1182/4885 |
| US-20100190779-A1 | VIRAL POLYMERASE INHIBITORS | POLR2A, POLR2H, POLR2E | LMNA 3643/4885APAF1 1250/4885POLB 11/4885 |
| US-20230037883-A1 | ALKENE-CONTAINING AMIDE COMPOUND AND APPLICATION THEREOF | DDT, ASPH, ALK | LMNA 4142/4885APAF1 2971/4885POLB 4307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.